1. Home
  2. |Insights
  3. |“Near” Not Indefinite if Adequately Defined

“Near” Not Indefinite if Adequately Defined

Client Alert | 1 min read | 07.03.07

In Young v. Lumenis, Inc. (No. 06-1455; Fed. Cir. 2007), a Federal Circuit reverses a district court decision and holds that the term “near” is not indefinite in view of the specification.

In finding the patent claim indefinite under Section 112, second paragraph, the district court relied on prior case law for the principle that a word of degree, such as “near,” can be indefinite when it fails to distinguish the invention over the prior art and does not permit one of ordinary skill to know what activity constitutes infringement. However, the Federal Circuit distinguishes that case law, finding that the intrinsic evidence here provides ample guidance on the meaning of “near.” Unlike a situation in which “at least about” precedes a term that was defined in the specification only by a broad range, the Young panel finds that the patent specification describes a narrow window within which to practice the claimed method and, in that unique context, the term “near” adequately notifies the public as to what conduct will constitute infringement.

Insights

Client Alert | 4 min read | 04.18.24

Maryland and Colorado Say the Price Isn’t Right: State Drug Affordability Review Boards Seek Drug Upper Payment Limits

Following federal lawmakers’ initiative to lower prescription drug prices under the Inflation Reduction Act of 2022, several states have taken similar steps to limit certain drugs’ prices. Drug affordability for consumers is a top priority for federal and state lawmakers and regulators because it is a bipartisan issue that directly impacts consumers’ wallets. With negotiations between the federal government and drug manufacturers over 10 drugs’ prices for Medicare beneficiaries well underway under the Inflation Reduction Act, 11 states, including Maryland and Colorado, have created drug affordability review boards to more directly tackle rising prices for both brand and generic drugs.[1] And another 12 states have pending legislation to create these boards.[2] ...